Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29848539 | 1.00 | LPL (0.47) | LPLLIPGCYP2A6DYRK1ACA1 | |
| SCHEMBL20427825 | 0.87 | LPL (0.38) | LPLLIPGCYP2A6CA2 | |
| SCHEMBL5314113 | 0.86 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20180186 | 0.85 | LIPG (0.51) | LPLLIPGDYRK1ACA2CA12 | |
| SCHEMBL1293460 | 0.79 | LPL (0.62) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29644319 | 0.79 | LPL (0.62) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16382818 | 0.78 | LPL (0.39) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1805374 | 0.78 | ACHE (0.42) | LPLLIPGDYRK1A | |
| SCHEMBL1294059 | 0.77 | LPL (0.61) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29387132 | 0.77 | LPL (0.61) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740948-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 1,3-BENZODIOXOLE DERIVATIVE COMPOUND | Dong Wha Pharm. Co., Ltd. (KR) | 2026-05-13 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025087274-A1 | AZABICYCLO DERIVATIVE AND PREPARATION METHOD THEREFOR, AND USE | 浙江海正药业股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| US-20250059180-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2025-02-20 | — | — | US | disclosed |
| EP-4464701-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | DONG WHA PHARM. CO., LTD. (KR) | 2024-11-07 | — | — | US | disclosed |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4277892-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2023-11-22 | — | — | EP | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| WO-2007114926-A2 | KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-10-11 | — | — | WO | disclosed |
| EP-1730116-B1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1730116-A1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2006125621-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
| WO-2005092863-A1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BAX, BCL2A1 | LPL 3805/4885LIPG 2561/4885CYP2A6 787/4885 |
| US-20250059180-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CYP2C9, CYP1B1, SULT1A1 | LPL 2984/4885LIPG 3537/4885CYP2A6 87/4885 |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | IL5, ACE2, IL15 | LPL 3407/4885LIPG 3149/4885CYP2A6 780/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | LPL 2/4885LIPG 17/4885CYP2A6 555/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | LPL 4579/4885LIPG 3220/4885CYP2A6 3411/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | LPL 4579/4885LIPG 3220/4885CYP2A6 3411/4885 |
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | HAVCR2, RPL35, ZC3HAV1L | LPL 1506/4885LIPG 1396/4885CYP2A6 322/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | LPL 4579/4885LIPG 3220/4885CYP2A6 3411/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | LPL 2/4885LIPG 8/4885CYP2A6 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.